Past Reports

Summary AirMedia has more than doubled in the past few weeks based solely on a supposed “investment” by A share company Shenzhen Liantronics. AirMedia did not disclose the actual contract,...

Summary Heavily promoted by multiple paid promoters (including undisclosed). Stock has spiked to an all-time high. Company is out of cash and is delinquent in its filings. Management with close...

Summary Companies who pay for stock promotion should be avoided. Period. Sell side research is woefully deficient and predictably biased. With technology, you get what you pay for. Lack of...

Summary Keryx has been marketing Auryxia off label conveying a “two for one benefit”. An “iron benefit” is absolutely critical to the successful marketing of the drug, but Auryxia has...

Summary Advaxis stock has recently quadrupled from $3 to as high as $13. Management has a history of promotional and misleading activities, including heavy use of the Dream Team Group....

Summary Support for TLPS was the brainchild of John Dooley of Jarvinian. The background of Dooley and Jarvinian show the risks of unbalanced optimism for unproven technologies. Other wireless constituents...

Summary Regulus is a retail heavy stock which has recently tripled on mere Phase I results. Regulus’ drug is not a one shot cure for Hep C and is inferior...

Summary CEO of Lion Biotech resigns following subpoena. Stock has fallen by 12% already. There is a wide web of parties with ties to Galena. Back in March, I highlighted the undisclosed...

Summary Globalstar currently sits under a large debt load of over $600 million even as it loses money every quarter. The most recent quarter showed only $4 million of EBITDA,...

Summary Straight Path holds wireless spectrum and patent troll assets. The stock is up by 100% in the past month, and is held overwhelmingly by retail investors. Announcements that it...

Summary Even after a recent drop, Globalstar is still up 7x from its 2013 lows. Yet the financials have deteriorated to the point of functional insolvency. Globalstar has all the...

Summary The fallout from stock promotions can far outweigh the prospects for a promising drug. Responses (and denials) from management are best viewed with a large grain of salt. There...

Summary Aemetis now has over $90 million in short-term debts coming due, but only $4.7 million in cash. The company has already begun defaulting on its short-term debts. This short-term...

Summary ChinaBak recently soared from below $2.50 to $5.00 “news” that LG was entering the China EV market and on subsequent EV subsidy news from China. But ChinaBak is not...

Summary Northwest Bio has been the subject of a massive promotional campaign which has seen the stock price soar. Many of the authors involved have close hidden ties to promotional...

Summary A recent report from Vista Partners sent OHRP soaring by 60%. The contents, including a $31 price target, was provided and paid for by Ohr management. Ohr stock had...

Summary Investors and analysts have overestimated the market size for SBC-102 by at least 3-9x. Most sufferers of CESD can be treated by proper diet and common statins (i.e. Lipitor)...

Summary ProActive Capital seeks to provide clarification. The firm says it was unaware of the Dream Team website. ProActive has now severed ties with Tech Guru, and says the contract...

This article is the opinion of the author. Nothing herein comprises a recommendation to buy or sell any security.  The author is short INO and UNIS. The author may choose...

Note: At least 13 recent articles covering CytRx have been removed from circulation at Seeking Alpha, the Wall Street Cheat Sheet, Motley Fool and Forbes. Many were removed in just...